Kosuke Hashimoto

872 total citations
35 papers, 598 citations indexed

About

Kosuke Hashimoto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Kosuke Hashimoto has authored 35 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology. Recurrent topics in Kosuke Hashimoto's work include Cancer Immunotherapy and Biomarkers (22 papers), Lung Cancer Treatments and Mutations (22 papers) and Lung Cancer Diagnosis and Treatment (11 papers). Kosuke Hashimoto is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Lung Cancer Treatments and Mutations (22 papers) and Lung Cancer Diagnosis and Treatment (11 papers). Kosuke Hashimoto collaborates with scholars based in Japan, United Kingdom and Italy. Kosuke Hashimoto's co-authors include Kunihiko Kobayashi, Hiroshi Kagamu, Ou Yamaguchi, Kyoichi Kaira, Yu Miura, Ayako Shiono, Yoshitake Murayama, Atsuto Mouri, Fuyumi Nishihara and Katsuhisa Horimoto and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Kosuke Hashimoto

33 papers receiving 596 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kosuke Hashimoto Japan 13 500 306 165 69 51 35 598
Virginia Palomar Coloma France 4 421 0.8× 190 0.6× 118 0.7× 30 0.4× 42 0.8× 5 481
Munehiro Ito Japan 8 481 1.0× 317 1.0× 81 0.5× 25 0.4× 26 0.5× 14 541
Andy Karabajakian France 9 537 1.1× 246 0.8× 138 0.8× 42 0.6× 103 2.0× 19 684
Vilma Graupner Switzerland 6 680 1.4× 484 1.6× 134 0.8× 39 0.6× 31 0.6× 8 725
R. Houston Thompson United Kingdom 2 520 1.0× 207 0.7× 312 1.9× 26 0.4× 92 1.8× 4 637
Iveta Kudaba Latvia 14 635 1.3× 490 1.6× 75 0.5× 42 0.6× 61 1.2× 24 750
Shawn W. Sun United States 8 597 1.2× 476 1.6× 106 0.6× 34 0.5× 27 0.5× 8 660
Audrey Simonaggio France 10 445 0.9× 278 0.9× 82 0.5× 22 0.3× 104 2.0× 23 567
Qiyun Ou China 8 366 0.7× 284 0.9× 137 0.8× 29 0.4× 124 2.4× 24 544
Nathan Comeaux United States 4 444 0.9× 308 1.0× 134 0.8× 62 0.9× 42 0.8× 9 559

Countries citing papers authored by Kosuke Hashimoto

Since Specialization
Citations

This map shows the geographic impact of Kosuke Hashimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kosuke Hashimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kosuke Hashimoto more than expected).

Fields of papers citing papers by Kosuke Hashimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kosuke Hashimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kosuke Hashimoto. The network helps show where Kosuke Hashimoto may publish in the future.

Co-authorship network of co-authors of Kosuke Hashimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Kosuke Hashimoto. A scholar is included among the top collaborators of Kosuke Hashimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kosuke Hashimoto. Kosuke Hashimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Imai, Hisao, Ayako Shiono, Kosuke Hashimoto, et al.. (2025). Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer. Anticancer Research. 45(2). 733–741. 1 indexed citations
2.
Endo, Satoshi, Hisao Imai, Atsuto Mouri, et al.. (2025). Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 151(1). 43–43. 2 indexed citations
3.
Hashimoto, Kosuke, Kyoichi Kaira, Atsuto Mouri, et al.. (2025). Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancer. Translational Lung Cancer Research. 14(4). 1242–1253.
4.
Hashimoto, Kosuke, Kyoichi Kaira, Hisao Imai, et al.. (2024). Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer. Cancer Imaging. 24(1). 157–157. 1 indexed citations
5.
Kaira, Kyoichi, Yoshinobu Ichiki, Hisao Imai, et al.. (2024). Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review. Translational Lung Cancer Research. 13(5). 1137–1149. 2 indexed citations
6.
Kaira, Kyoichi, Hisao Imai, Atsuto Mouri, et al.. (2023). Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib. Thoracic Cancer. 14(29). 2950–2961. 3 indexed citations
7.
Yamaguchi, Ou, Kyoichi Kaira, Hisao Imai, et al.. (2023). Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer. Oncology. 102(3). 271–282. 10 indexed citations
8.
Hashimoto, Kosuke, Ryo Taguchi, Hisao Imai, et al.. (2023). A Th1-like CD4+ T-cell Cluster That Predicts Disease-free Survival in Early-stage Lung Cancer. Cancer Research Communications. 3(7). 1277–1285. 3 indexed citations
9.
Kagamu, Hiroshi, Shigehisa Kitano, Ou Yamaguchi, et al.. (2022). Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy. Cancer Research. 82(24). 4641–4653. 27 indexed citations
10.
Shiono, Ayako, Hisao Imai, Ryo Taguchi, et al.. (2022). Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa‐associated lymphoid tissue lymphoma: A case report. Cancer Reports. 5(10). e1689–e1689. 1 indexed citations
11.
Hashimoto, Kosuke, Kyoichi Kaira, Hisao Imai, et al.. (2022). Prognostic Potential of Metabolic Activity on 18F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade. Journal of Immunotherapy. 45(8). 349–357. 5 indexed citations
12.
Yamaguchi, Ou, Kenichi Yoshimura, Ayako Shiono, et al.. (2022). Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. BMC Cancer. 22(1). 1325–1325. 3 indexed citations
13.
Mouri, Atsuto, Kyoichi Kaira, Ou Yamaguchi, et al.. (2021). Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. Frontiers in Oncology. 11. 610952–610952. 11 indexed citations
14.
Imai, Hisao, Ou Yamaguchi, Kosuke Hashimoto, et al.. (2021). Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma. Chemotherapy. 66(3). 65–71. 4 indexed citations
15.
Yamaguchi, Ou, Kyoichi Kaira, Kosuke Hashimoto, et al.. (2020). Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%. Scientific Reports. 10(1). 14990–14990. 24 indexed citations
16.
Yamaguchi, Ou, Kyoichi Kaira, Kosuke Hashimoto, & Hiroshi Kagamu. (2020). Detection of pseudoprogression with [18F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment. European Journal of Nuclear Medicine and Molecular Imaging. 48(4). 1268–1270. 2 indexed citations
17.
Kagamu, Hiroshi, Shigehisa Kitano, Ou Yamaguchi, et al.. (2019). CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. Cancer Immunology Research. 8(3). 334–344. 169 indexed citations
18.
Yamaguchi, Ou, Kyoichi Kaira, Atsuto Mouri, et al.. (2019). Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. Cancer Chemotherapy and Pharmacology. 83(5). 817–825. 12 indexed citations
19.
Mouri, Atsuto, Kyoichi Kaira, Ou Yamaguchi, et al.. (2019). Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. Cancer Chemotherapy and Pharmacology. 84(4). 873–880. 35 indexed citations
20.
Kaczkowski, Bogumił, Kosuke Hashimoto, & Piero Carninci. (2016). Epi-drivers and cancer-testis genes. Translational Cancer Research. 5(3). 334–336. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Virginia Palomar Coloma Breakdown of academic impact, for papers by Munehiro Ito Breakdown of academic impact, for papers by Andy Karabajakian Breakdown of academic impact, for papers by Vilma Graupner Breakdown of academic impact, for papers by R. Houston Thompson Breakdown of academic impact, for papers by Iveta Kudaba Breakdown of academic impact, for papers by Shawn W. Sun Breakdown of academic impact, for papers by Audrey Simonaggio Breakdown of academic impact, for papers by Qiyun Ou Breakdown of academic impact, for papers by Nathan Comeaux
Rankless by CCL
2026